FindTrial
Sign In

Understanding Muscle Weakness and Nerve Function in Guillain-Barr Syndrome Using Blood Markers and Autonomic Tests

Biomarkers and Autonomic Dysfunction in Sarcopenia Evaluation for Guillain-Barr Syndrome (BASE-GBS): A Prospective Cohort Study - BASE-GBS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089392
Enrollment
94
Registered
2025-06-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G610- Guillain-Barre syndrome

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Shweta Suresh Naik
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults aged 18-75 years with a confirmed diagnosis of GBS admitted in ICU. 2. Informed consent obtained from patients or their legal representatives.

Exclusion criteria

Exclusion criteria: 1. Conditions causing sarcopenia independent of critical illness (e.g., advanced chronic kidney disease, liver disease).

Design outcomes

Primary

MeasureTime frame
1.To study the incidence and severity of sarcopenia in GBS patients using Body composition analysis Timepoint: day0,7,14 or discharge—

Secondary

MeasureTime frame
2. To predict the incidence and severity of sarcopenia in GBS patients using ultrasound, markers of autonomic function and biochemical biomarkers. Timepoint: day0,7,14 or discharge—

Countries

India

Contacts

Public ContactShweta Suresh Naik

National Institute of Mental Health and Neurosciences

neurodocms@gmail.com9986308719

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026